Mark Alles is an accomplished biopharmaceutical executive who led successful global oncology-focused organizations over his more than three-decade career. He is the former chairman and CEO of Celgene Corporation, a global biopharmaceutical company, where he drove growth and medical innovation throughout his 15-year tenure until its $74-billion acquisition by Bristol Myers Squibb in 2019.
Mr. Alles brings deep operational, financial, business development and commercial experience to the Turning Point board. He led the expansion of Celgene from a U.S. based organization with less than 500 employees to a global company serving patients in more than 50 countries with 8,800 employees. Prior to being named chair in 2018 and CEO in 2016, Mr. Alles served as Celgene president and chief operating officer, executive vice president and Global Head of Hematology & Oncology and chief commercial officer. Before joining Celgene in 2004, he was vice president of the U.S. Oncology business unit at Aventis Pharmaceuticals where he also served in other senior management roles during an 11-year period. He began his career in the biopharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson.
Mr. Alles is a member of the board of directors for Antengene Corporation and Syros Pharmaceuticals. He is a former board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Biotechnology Innovation Organization (BIO).
He earned his B.S. degree from Lock Haven University of Pennsylvania and served as a captain in the United States Marine Corps.